Read, Watch or Listen

Affordable generic versions of lenacapavir, a groundbreaking twice-yearly HIV prevention injection, will be available in 120 low- and middle-income countries by 2027. Priced at $40 per patient annually, this injectable PrEP offers a transformative solution to combatting HIV, especially for those who struggle with daily medication adherence. The initiative, a collaboration between Gilead, generic manufacturers, and global health organizations like Unitaid and the Gates Foundation, aims to significantly reduce new HIV infections. While hailed as a major step forward, concerns remain about funding limitations and potential access barriers in countries not included in the initial agreement.

Prepared by Olivia Bennett and reviewed by editorial team.